Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT04362644RecruitingPhase 1
Imaging agent study for idiopathic pulmonary fibrosis lung scarring
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Birmingham, AlabamaAges 40–85 - NCT04016181Enrolling by invitation
Study to categorize lung fibrosis types at a clinic
This study enrolls people who have interstitial lung disease and are seen at the Edinburgh lung fibrosis clinic. It aims to sort different underlying “types” of lung fibrosis so doctors can better understand and potentially guide care.
Ages 18–99 - NCT03535545RecruitingPhase 1
PET-MRI imaging test in lung cancer and lung disease
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
Boston, MassachusettsAges 18–80 - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+ - NCT00258570Recruiting
Study genetics in idiopathic pulmonary fibrosis patients
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07251725Recruiting
Genetic study of family-linked lung scarring
This study looks for genetic causes of pulmonary fibrosis that runs in families. You and your affected family member(s) would provide blood samples and health info to help researchers understand why lung scarring happens.
Pavia, LombardyAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT05042219Recruiting
How lung disease treatment may affect heart function
This study looks at how common long-term lung conditions and their treatments may change heart function. It uses heart imaging (an MRI) to see what’s happening, which could help doctors better monitor heart risks in people with lung disease.
AachenAges 18–99 - NCT07869147RecruitingPhase 2
Study of ORJ-001 for idiopathic pulmonary fibrosis
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
Doral, FloridaAges 40 years+ - NCT07194382RecruitingPhase 2
Testing a new liquid form of nintedanib for IPF
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Camperdown, New South WalesAges 40 years+ - NCT04442711Recruiting
Study of worsening lung symptoms in people with IPF
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
Hellerup, CopenhagenAges 18 years+ - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Birmingham, AlabamaAges 40 years+ - NCT07482917Recruiting
Streamlining the diagnosis of interstitial lung disease
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
Granollers, BarcelonaAges 18 years+ - NCT07454291RecruitingPhase 1
How taladegib works in healthy volunteers
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
Brisbane, QueenslandAges 26–65 - NCT07407543RecruitingPhase 1
Study of SRN001 in healthy Korean and Caucasian men
This trial tests a new drug called SRN001 in healthy men to see how safe it is and how the body processes it. It may help find the right dose for future studies.
SeoulAges 19–60 - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT07019714Recruiting
A movement therapy to improve walking ability in IPF
This trial tests a gentle exercise technique (Daoyin) to help people with Idiopathic Pulmonary Fibrosis (IPF) feel less short of breath and walk farther. It is done at home with a smartphone or computer.
Beijing, Beijing MunicipalityAges 40–85
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 86 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.